Which GLP-1 agonist is used solely for weight loss?

Wegovy is specifically indicated for weight management in individuals with obesity or overweight who have at least one weight-related condition. It is a higher-dose formulation of semaglutide, which functions as a GLP-1 receptor agonist to help regulate appetite and promote weight loss. This medication targets weight loss as its primary use, distinguishing it from other GLP-1 agonists that are also prescribed for the management of type 2 diabetes.

For instance, Trulicity and Ozempic are primarily approved for treating type 2 diabetes and while they may have weight loss effects, their main indication is not weight management. Mounjaro, also used for diabetes treatment, has potential weight loss benefits but is not solely indicated for that purpose. Thus, Wegovy is the only GLP-1 agonist listed that is explicitly formulated and approved for weight loss as its primary indication.